CTRI/2023/10/059222招募中3 期
A Prospective, Multi-center, Randomized, Double blind, Parallel-group, Active-controlled, Phase III Study to Compare the Efficacy, Safety and Immunogenecity of Regenix Biosciences Limited,India, Insulin Glargine 100units/mL (U-100) (Investigational drug) with Lantus® (Insulin Glargine) of Sanofi-aventis, India, (Reference drug) in Type I and Type II Diabetes patients - Nil
Regenix Biosciences Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients who understand and agrees to comply with the study procedure and provide written informed consent.
- •2. Patients who have been diagnosed as cases of diabetes (Fasting C-peptide less than 0.2 nmol/L) and have been on a stable dose of insulin for at least 3 months prior to inclusion in the trial. A stable dose is defined as the dose staying within +/- 10%.
- •3. Male or female patients between 18 to 65 years of age.
- •4. Patients with body mass index (BMI) 18.0 to 35.0 kg/m2
- •5. Patients with glycosylated hemoglobin (HbA1c) levels between 7.5 and 10.0% both inclusive.
- •6. Patients who are cooperative, reliable, and agree to have regular injections of insulin and are willing to comply with protocol procedures.
- •7. Female patients (non-pregnant and non lactating with adequate protection from conception). Females of childbearing potential must agree to use an acceptable method of birth control (including barrier method contraceptives or intrauterine device). Women with history of bilateral tubal ligation, women who have undergone total hysterectomy or women who are two years post-menopausal are also eligible.
- •8. Ability to use the self-glucose-monitoring device and self-inject insulin.
排除标准
- •Patients will not be allowed to enter the study if they meet any of the following criteria
- •1. Patient who is pregnant or is currently breast-feeding.
- •2. Patient with compromised hepatic or renal function, as shown by but not limited to baseline AST or ALT 3 times the upper limit of normal range, serum creatinine 2.0 mg/dl and/or BUN 30 mg/dl, respectively. Abnormal findings should be discussed with the medical monitor prior to the patient’s
- •3. Patient who has been treated with other investigational agent or devices within the previous 30 days, has planned use of investigational drugs or devices, or has been previously randomized in this trial.
- •4. Patient with history or evidence of allergy to insulin preparations.
- •5. Patient with history or evidence of recurrent severe hypoglycemia.
- •6. Patient whose requirement for total daily dose of insulin is 1.4 units/kg
- •7. Patient who has received Insulin Glargine or Sanofi-aventis’s Lantus (Insulin Glargine), for the previous one year
- •8. Patients with serum anti-insulin antibody (AIA) level above 20 micro U/ml.
- •9. Patient who has received any insulin of animal origin during the last 3 years.
- •10. Patients who are currently receiving or have received within the last year any immune modulators medications, including corticosteroids that would possibly modify antibody generation either at the enrollment or during the course of the study. Topical/ ophthalmic/intra articular/nasal spray
- •corticosteroids will be allowed.
- •11. Patients who are Hepatitis B or C or HIV positive.
- •12. Patients who have undergone pancreatectomy or pancreas/islet cell transplant.
- •13. Patients unlikely to comply with the study protocol e.g., unable to return periodically for subsequent visits.
- •14. Patient with history or evidence of active severe proliferative retinopathy, nephropathy and/or neuropathy significant cardiovascular disease, anemia or hemoglobinopathy, hypothyroidism, alcohol or drug abuse or any other medical condition that in the opinion of Investigator can interfere with the study.
- •15. Patients who are judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned above.
研究者
相似试验
已完成
3 期
A multi-center study to compare the effectiveness and safety of two different insulin injectable suspensions in treatment of patients diagnosed with type 2 diabetes mellitusCTRI/2017/02/007763MJ Biopharm Private Limited200
尚未招募
3 期
Effect of Eluxadoline in Comparison to Mebeverine for Treatment of Patients With Diarrhoea-Predominant Irritable Bowel SyndromeCTRI/2024/02/062593Sun Pharmaceutical Industries Limited
招募中
3 期
Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when given in combination with Paclitaxel in patients diagnosed with HER2 Positive Metastatic Breast CancerCTRI/2017/02/007892Glenmark Pharmaceuticals Ltd
已完成
3 期
A Clinical Trial to Evaluate the Efficacy, Safety of Fesoterodine Fumarate Extended Release Tablets 4 mg / 8 mg Versus Solifenacin Succinate Tablets 5 mg/10 mg in Adult Patients Diagnosed with Overactive Bladder with Symptoms of Urge Urinary Incontinence, Urgency, and Frequency.CTRI/2021/12/038596MSN Laboratories Private Limited216
已完成
不适用
This is a clinical trial to compare clinical efficacy, safety and tolerability of generic Diclofenac Sodium Topical Gel 1%, with Voltaren® Gel (a Diclofenac Sodium Topical Gel 1%) and Vehicle of Diclofenac Sodium Topical Gel 1% in subjects with osteoarthritis(degenerative joint disease) of the kneeCTRI/2015/09/006149Cipla Limited990